EGFR and pancreatic neoplasm: We supplemented Etanercept and Dacomitinib to DDIT4-AS1-overexpression-BxPC-3 cells and found that the TNF or ErbB signaling pathway did not have obvious effects on the stemness of pancreatic cancer cells (Fig. S2f-i).